{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:10:51Z","timestamp":1772842251521,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen Clinical Research Center for Tuberculosis","award":["20210617141509001"],"award-info":[{"award-number":["20210617141509001"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2308300"],"award-info":[{"award-number":["2023YFC2308300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenzhen Municipal Basic Research Program","award":["JCYJ2-24-813101908012"],"award-info":[{"award-number":["JCYJ2-24-813101908012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12036-5","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:20:35Z","timestamp":1763547635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Concentration of contezolid in cerebrospinal fluid and serum in a patient with renal allograft tuberculosis and tuberculous meningoencephalitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Weijian","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peize","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"1","key":"12036_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s41182-025-00738-0","volume":"53","author":"M Maleki Rad","year":"2025","unstructured":"Maleki Rad M, Haddad M, Sheybani F, Shirazinia M, Dadgarmoghaddam M. Mortality predictors and diagnostic challenges in adult tuberculous meningitis: a retrospective cohort of 100 patients. Trop Med Health. 2025;53(1):58. https:\/\/doi.org\/10.1186\/s41182-025-00738-0.","journal-title":"Trop Med Health"},{"issue":"10159","key":"12036_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/s0140-6736(18)32203-7","volume":"392","author":"regional Global","year":"2018","unstructured":"Global regional. National age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736\u201388. https:\/\/doi.org\/10.1016\/s0140-6736(18)32203-7.","journal-title":"Lancet"},{"issue":"3","key":"12036_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5500\/wjt.v7.i3.213","volume":"7","author":"M Anand","year":"2017","unstructured":"Anand M, Nayyar E, Concepcion B, Salani M, Schaefer H. Tuberculosis in kidney transplant recipients: a case series. World J Transpl. 2017;7(3):213\u201321. https:\/\/doi.org\/10.5500\/wjt.v7.i3.213.","journal-title":"World J Transpl"},{"key":"12036_CR4","doi-asserted-by":"publisher","unstructured":"Krishnamoorthy S, Kumaresan N, Zumla A. Latent tuberculosis infection and renal transplantation-diagnosis and management. Int J Infect Dis. 2019;80s(S73\u2013s76). https:\/\/doi.org\/10.1016\/j.ijid.2019.01.049.","DOI":"10.1016\/j.ijid.2019.01.049"},{"issue":"13","key":"12036_CR5","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s40265-021-01576-0","volume":"81","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Contezolid: first approval. Drugs. 2021;81(13):1587\u201391. https:\/\/doi.org\/10.1007\/s40265-021-01576-0.","journal-title":"Drugs"},{"key":"12036_CR6","doi-asserted-by":"publisher","first-page":"1067516","DOI":"10.3389\/fmed.2022.1067516","volume":"9","author":"C Wang","year":"2022","unstructured":"Wang C, Wang G, Huo F, Xue Y, Jia J, Dong L, Zhao L, Wang F, Huang H, Duan H. Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant mycobacterium tuberculosis in China. Front Med (Lausanne). 2022;9:1067516. https:\/\/doi.org\/10.3389\/fmed.2022.1067516.","journal-title":"Front Med (Lausanne)"},{"key":"12036_CR7","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.2147\/idr.S425743","volume":"16","author":"J Wang","year":"2023","unstructured":"Wang J, Nie W, Ma L, Li Q, Geng R, Shi W, Chu N. Clinical utility of contezolid-containing regimens in 25 cases of linezolid-intolerable tuberculosis patients. Infect Drug Resist. 2023;16:6237\u201345. https:\/\/doi.org\/10.2147\/idr.S425743.","journal-title":"Infect Drug Resist"},{"key":"12036_CR8","doi-asserted-by":"publisher","unstructured":"Shoen C, De Stefano M, Hafkin B, Cynamon M. In vitro and in vivo activities of contezolid (MRX-I) against mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;62(8). https:\/\/doi.org\/10.1128\/aac.00493-18.","DOI":"10.1128\/aac.00493-18"},{"issue":"3","key":"12036_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1021\/acsptsci.0c00041","volume":"3","author":"A Wright","year":"2020","unstructured":"Wright A, Deane-Alder K, Marschall E, Bamert R, Venugopal H, Lithgow T, Lupton DW, Belousoff MJ. Characterization of the core ribosomal binding region for the Oxazolidone family of antibiotics using Cryo-EM. ACS Pharmacol Transl Sci. 2020;3(3):425\u201332. https:\/\/doi.org\/10.1021\/acsptsci.0c00041.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"11","key":"12036_CR10","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1021\/jm401931e","volume":"57","author":"MF Gordeev","year":"2014","unstructured":"Gordeev MF, Yuan ZY. New potent antibacterial Oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014;57(11):4487\u201397. https:\/\/doi.org\/10.1021\/jm401931e.","journal-title":"J Med Chem"},{"issue":"2","key":"12036_CR11","doi-asserted-by":"publisher","first-page":"106875doi","DOI":"10.1016\/j.ijantimicag.2023.106875","volume":"62","author":"W Guo","year":"2023","unstructured":"Guo W, Hu M, Xu N, Shangguan Y, Xia J, Hu W, Li X, Zhao Q, Xu K. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: a case report. Int J Antimicrob Agents. 2023;62(2):106875doi. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106875.","journal-title":"Int J Antimicrob Agents"},{"key":"12036_CR12","doi-asserted-by":"publisher","first-page":"1224179","DOI":"10.3389\/fmed.2023.1224179","volume":"10","author":"Z Xu","year":"2023","unstructured":"Xu Z, Zhang J, Guan T, Wan G, Jiang C, Lang L, Wang L. Case report: successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid. Front Med (Lausanne). 2023;10:1224179. https:\/\/doi.org\/10.3389\/fmed.2023.1224179.","journal-title":"Front Med (Lausanne)"},{"key":"12036_CR13","doi-asserted-by":"publisher","first-page":"101523","DOI":"10.1016\/j.trim.2021.101523","volume":"70","author":"J Zou","year":"2022","unstructured":"Zou J, Wang T, Qiu T, Chen Z, Zhou J, Ma X, Jin Z, Xu Y, Zhang L. Clinical characteristics of tuberculous infection following renal transplantation. Transpl Immunol. 2022;70:101523. https:\/\/doi.org\/10.1016\/j.trim.2021.101523.","journal-title":"Transpl Immunol"},{"issue":"7","key":"12036_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cmi.2015.03.010","volume":"21","author":"N Benito","year":"2015","unstructured":"Benito N, Garc\u00eda-V\u00e1zquez E, Horcajada JP, Gonz\u00e1lez J, Oppenheimer F, Cof\u00e1n F, Ricart MJ, Rimola A, Navasa M, Rovira M, et al. Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: a retrospective matched cohort study. Clin Microbiol Infect. 2015;21(7):651\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2015.03.010.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"12036_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1080\/23744235.2020.1789212","volume":"52","author":"V Pintado","year":"2020","unstructured":"Pintado V, Pazos R, Jim\u00e9nez-Mej\u00edas ME, Rodr\u00edguez-Guardado A, D\u00edaz-Poll\u00e1n B, Cabellos C, Garc\u00eda-Lechuz JM, Lora-Tamayo J, Domingo P, Mu\u00f1ez E, et al. Linezolid for therapy of staphylococcus aureus meningitis: a cohort study of 26 patients. Infect Dis (Lond). 2020;52(11):808\u201315. https:\/\/doi.org\/10.1080\/23744235.2020.1789212.","journal-title":"Infect Dis (Lond)"},{"issue":"3","key":"12036_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/17512433.2019.1552831","volume":"12","author":"FV Cresswell","year":"2019","unstructured":"Cresswell FV, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, Van Crevel R. Intensified antibiotic treatment of tuberculosis meningitis. Expert Rev Clin Pharmacol. 2019;12(3):267\u201388. https:\/\/doi.org\/10.1080\/17512433.2019.1552831.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"12036_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","volume":"60","author":"MGG Sturkenboom","year":"2021","unstructured":"Sturkenboom MGG, M\u00e4rtson AG, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SHJ, Denti P, Peloquin CA, Aarnoutse RE, Alffenaar JC. Population pharmacokinetics and bayesian dose adjustment to advance TDM of anti-TB drugs. Clin Pharmacokinet. 2021;60(6):685\u2013710. https:\/\/doi.org\/10.1007\/s40262-021-00997-0.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"12036_CR18","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.5588\/ijtld.18.0822","volume":"23","author":"Z Lifan","year":"2019","unstructured":"Lifan Z, Sainan B, Feng S, Siyan Z, Xiaoqing L. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019;23(12):1293\u2013307. https:\/\/doi.org\/10.5588\/ijtld.18.0822.","journal-title":"Int J Tuberc Lung Dis"},{"key":"12036_CR19","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.2147\/idr.S468543","volume":"17","author":"X Ma","year":"2024","unstructured":"Ma X, Zhang R, Cai X, Lang Y, Wang H, Li J. Plasma concentrations of contezolid and its efficacy and safety in elderly patients with multidrug-resistant tuberculosis and renal insufficiency. Infect Drug Resist. 2024;17:3047\u201356. https:\/\/doi.org\/10.2147\/idr.S468543.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"12036_CR20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.clinthera.2020.03.020","volume":"42","author":"L Li","year":"2020","unstructured":"Li L, Wu H, Chen Y, Yuan H, Wu J, Wu X, Zhang Y, Cao G, Guo B, Wu J, et al. Population pharmacokinetics study of contezolid (MRX-I), a novel oxazolidinone antibacterial agent, in Chinese patients. Clin Ther. 2020;42(5):818\u201329. https:\/\/doi.org\/10.1016\/j.clinthera.2020.03.020.","journal-title":"Clin Ther"},{"issue":"6","key":"12036_CR21","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.clinthera.2019.04.025","volume":"41","author":"J Wu","year":"2019","unstructured":"Wu J, Wu H, Wang Y, Chen Y, Guo B, Cao G, Wu X, Yu J, Wu J, Zhu D, et al. Tolerability and pharmacokinetics of contezolid at therapeutic and supratherapeutic doses in healthy Chinese subjects, and assessment of contezolid dosing regimens based on pharmacokinetic\/pharmacodynamic analysis. Clin Ther. 2019;41(6):1164\u2013e11741164. https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.025.","journal-title":"Clin Ther"},{"key":"12036_CR22","doi-asserted-by":"publisher","unstructured":"Eckburg PB, Ge Y, Hafkin B. Single-and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects. Antimicrob Agents Chemother. 2017;61(4). https:\/\/doi.org\/10.1128\/aac.02181-16.","DOI":"10.1128\/aac.02181-16"},{"key":"12036_CR23","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2147\/idr.S465350","volume":"17","author":"W Liu","year":"2024","unstructured":"Liu W, Yang L, Qin H, Zhang P. Successful treatment of intractable tuberculous peritonitis in a woman with chronic kidney allograft dysfunction using contezolid containing regimen. Infect Drug Resist. 2024;17:2713\u20138. https:\/\/doi.org\/10.2147\/idr.S465350.","journal-title":"Infect Drug Resist"},{"key":"12036_CR24","doi-asserted-by":"publisher","first-page":"1258561","DOI":"10.3389\/fcimb.2023.1258561","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Yu Z, Jiang Y, Lao S, Li D. Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review. Front Cell Infect Microbiol. 2023;13:1258561. https:\/\/doi.org\/10.3389\/fcimb.2023.1258561.","journal-title":"Front Cell Infect Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12036-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:20:36Z","timestamp":1763547636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-12036-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12036"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12036-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that written informed consent has been obtained from the patient involved in the case report. Ethics approval is not needed for case reports according to our institutional (The Third People\u2019s Hospital of Shenzhen) review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the clinical details and clinical images were obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1615"}}